Business Context and Reporting Period
This Form 6-K filing by Novartis AG, dated June 26, 2002, serves as a pre-results announcement and invitation for a conference call regarding First Half 2002 sales and results. The document primarily provides a detailed quarterly breakdown of financial performance for the full fiscal year 2001, updated to reflect the split of the Consumer Health sector into OTC, Medical Nutrition, and Infant & Baby divisions.
Key Financial Metrics (Fiscal Year 2001)
| Metric | Value (CHF millions) |
|---|---|
| Total Sales | 31,643 |
| Operating Income | 7,277 |
| Net Income | 7,024 |
| Operating Margin (Group) | 23.0% |
| Pharmaceuticals Sales | 20,181 |
| Pharmaceuticals Operating Income | 5,677 |
| Research & Development Expenses | 4,189 |
The filing does not provide specific figures for debt, liquidity, or cash flow for the 2001 period or the first half of 2002.
Material Changes and Adjustments
The filing details sales adjustments totaling CHF 395 million for the full year 2001 due to changes in accounting policy regarding sales incentives and discounts to retailers. The largest adjustments occurred in the Infant & Baby sector (CHF 216 million) and OTC sector (CHF 129 million). Quarterly operating margins varied significantly by sector, with Pharmaceuticals maintaining a stable margin around 28%, while CIBA Vision fluctuated between 1.4% in Q1 and 17.7% in Q2.
Guidance, Outlook, and Risks
This document does not contain specific financial guidance, forward-looking statements, or risk factors for the upcoming period. It functions as a data release for historical 2001 performance and an invitation for management commentary on First Half 2002 results, which were scheduled to be discussed on July 22, 2002. No unusual items or contingencies are explicitly detailed in the text provided.
Investor Verification Checklist
- Verify the First Half 2002 sales and results figures during the scheduled conference call on July 22, 2002, as they are not included in this filing.
- Confirm the impact of the CHF 395 million sales adjustments on year-over-year growth comparisons.
- Review the specific performance of the newly split Consumer Health sub-sectors (OTC, Medical Nutrition, Infant & Baby) in the upcoming 2002 report.
- Check for updated debt and liquidity metrics in the full 2002 interim report, as they are absent here.